ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 056

Journey Maps of the Diagnostic Process: Insights from Caregivers of Patients with Juvenile Idiopathic Arthritis

Costello Anna1, Anyun Chatterjee2, Lanelle Quzack2, Ashley Meyer2, Jahan Jazayeri3, Amarpreet Kaur2, Pamela Weiss4, Katherine Kellom2 and Irit Rasooly2, 1Children's Hospital of Philadelphia, PA, 2Children's Hospital of Philadelphia, 3Quinnipiac University, 4Childrens Hospital of Philadelphia, Philadelphia, PA

Meeting: 2026 Pediatric Rheumatology Symposium

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Thursday, March 19, 2026

Title: Posters: Quality, Health Services, and Education Research I

Session Time: 6:00PM-7:00PM

Background/Purpose: Early diagnosis and treatment of Juvenile Idiopathic Arthritis (JIA) minimizes the accrual of joint damage and improves long-term outcomes. However, many patients with JIA experience a prolonged, circuitous path to diagnosis. This study explores the experiences of caregivers of patients with JIA during the diagnostic journey to identify common patterns and experiences and to create journey maps of the diagnostic process. 

Methods: We utilized semi-structured qualitative interviews with caregivers of children diagnosed with JIA between 2023 and 2025. Interviewees were purposively sampled from patients with short (<10 weeks, n=10), medium (10-24 weeks, n=10) or long ( >24 weeks, n=10) time to diagnosis. Using NVivo for data coding and an inductive analysis approach, we identified common patterns and experiences of the journey to JIA diagnosis, exploring variation across comparison groups. We generated journey maps (Figure 1) as an analytic strategy, guiding theme development and allowing for cross-case comparison. 

Results: Interviewees (n=30, Table 1) reported that early symptoms, like non-specific joint pain, were often interpreted by parents and clinicians as sports-related trauma, overuse injuries, or growing pains. Once children exhibited joint swelling or functionally limiting symptoms, such as limping, there was an inflection point in the diagnostic process; parents experienced heightened concern and presented for more care. It often required multiple visits for parental concern to converge with clinician concern, and frequently multiple providers were seen before JIA was considered as a possible diagnosis. The most common provider types seen were primary care providers, emergency department/urgent care providers, and orthopedists. Common patterns identified in cases with a more prolonged path to diagnosis included (1) minimization of symptoms by caregivers, (2) non-specific symptoms or waxing and waning symptoms that  overlap with other common childhood conditions, (3) lack of provider familiarity with inflammatory arthritis or provider dismissiveness of parental concerns, and (4) scheduling delays.  Common patterns identified in cases with a more direct path to diagnosis included (1) parental advocacy and perseverance, (2) factors that resulted in ease of accessing care and scheduling appointments, and (3) familiarity with autoimmune conditions (Table 2).   Interviewees reported they might have sought care more urgently if they had known about JIA and that many clinicians seem to lack awareness of JIA. 

Conclusion: Patients with JIA often experience prolonged, indirect paths to diagnosis. This circuitous diagnostic journey is likely multifactorial with contributions from minimization of symptoms by caregivers, non-specific symptoms that overlap with more common conditions, lack of clinician familiarity with the condition, and scheduling delays. We have generated representative journey maps of archetypal diagnostic trajectories. Increased awareness of early signs and symptoms of JIA amongst caregivers and clinicians could facilitate a more timely, direct diagnostic path and earlier referral to rheumatology. 

Cohort DemographicsSupporting image 1

Figure 1: Diagnostic Journey MapSupporting image 2

Table 2: Common Patterns with Representative QuotesSupporting image 3


Disclosures: C. Anna: None; A. Chatterjee: None; L. Quzack: None; A. Meyer: None; J. Jazayeri: None; A. Kaur: None; P. Weiss: Bristol-Myers Squibb(BMS), 1, Novartis, 12, Publication support, Pfizer, 1, 6, Up to Date, 9; K. Kellom: None; I. Rasooly: None.

To cite this abstract in AMA style:

Anna C, Chatterjee A, Quzack L, Meyer A, Jazayeri J, Kaur A, Weiss P, Kellom K, Rasooly I. Journey Maps of the Diagnostic Process: Insights from Caregivers of Patients with Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 3). https://acrabstracts.org/abstract/journey-maps-of-the-diagnostic-process-insights-from-caregivers-of-patients-with-juvenile-idiopathic-arthritis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2026 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/journey-maps-of-the-diagnostic-process-insights-from-caregivers-of-patients-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology